1009119-83-8

Usage

Uses

Used in Pharmaceutical Industry:
1H-IMidazole, 5,5'-[1,1'-biphenyl]-4,4'-diylbis[2-(2S)-2-pyrrolidinyl-, hydrochloride (1:4) is used as a drug candidate for the treatment of hepatitis C (HCV) due to its ability to inhibit the HCV protein NS5A. This inhibition can help in controlling the replication of the virus and managing the disease progression in infected individuals.

Upstream product

• 1007882-23-6 methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate 
• 5467-72-1 α-amino-4-bromoacetophenone hydrochloride 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 1007882-12-3 (S)-tert-butyl 2-(5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1007881-98-2 y 
• 1007882-04-3 (S)-tert-butyl 2-(5-(4-bromophenyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1009119-82-7 1,2-pyrrolidinedicarboxylic acid, 2,2’-[[1,1’-biphenyl]-4,4’-diylbis(2-oxo-2,1-ethanediyl)] bis[1-(1,1-dimethylethyl)] ester, (2S)- 

Relevant academic research and scientific papers

MICRO-ELECTROLYSIS REACTOR FOR ULTRA FAST, OXIDANT FREE, C-C COUPLING REACTION AND SYNTHESIS OF DACLATASVIR ANALOGS THEREOF

The present invention relates to a continuous micro-electro-flow reactor system for ultra-fast, oxidant free, C—C coupling reaction for making symmetrical biaryls and analogs thereof. This invention further relates to the said process for preparation of antiviral drug, daclatasvir of general formula I.

PROCESS FOR PREPARATION OF DACLATASVIR AND SALTS

The present invention relates to crystalline daclatasvir dihydrochloride hydrate and process for its preparation.

Synthetic method of daclatasvir

The invention discloses a synthetic method of daclatasvir. The method adopts bis(2-bromoacetyl) biphenyl and t-butyloxycarboryl-L-proline as initial raw materials, the initial raw materials are separately synthesized into a midbody N-4, N-3, N-2 and N-1 i

Preparation method of daclatasvir and its intermediate

The invention discloses a preparation method of daclatasvir and its intermediate. The invention provides a preparation method of a daclatasvir intermediate I. The method includes the step of: in an organic solvent or under a solvent-free condition, subjec

Anti-hepatitis C Daclatasvir synthesis method

The invention discloses an anti-hepatitis C Daclatasvir synthesis method. The anti-hepatitis C Daclatasvir synthesis method comprises the following steps that 1, 4,4'-di(2-chloracetyl) biphenyl and Boc-L-proline perform condensation to generate ester; 2,

DACLATASVIR FREE BASE AND PROCESS FOR THE PREPARATION THEREOF

The present invention relates to daclatasvir free base, processes for its preparation, a process for its conversion into pharmaceutically acceptable salts of daclatasvir. The present invention also relates to a process for the preparation and purification

Novel method for synthesizing dimethyl dicarbamate dihydrochloride compound

The invention relates to a novel method for synthesizing N,N'[[1,1'-biphenyl]4, 4'-diyl bis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-ethylmethyl)-2-oxo-2,1-ethanediyl]]] dimethyl dicarbamate dihydrochloride. According to the novel method d

PROCESS FOR THE PREPARATION OF DACLATASVIR

The present disclosure provides a novel process for the preparation of daclatasvir or pharmaceutically acceptable salts thereof using novel intermediates. Formula (I)

Design, synthesis and evaluation of novel anti-HCV molecules that deliver intracellularly three highly potent NS5A inhibitors

The design and synthesis of new non-symmetrical NS5A inhibitors with sulfur containing amino acids is reported along with their ability to block HCV replication in an HCV 1b replicon system. These compounds display EC50 values in the picomolar range with a large therapeutic index (>106). Moreover, cellular pharmacology studies show that our preferred compounds intracellularly deliver three potent NS5A inhibitors.

CRYSTALLINE FORM OF METHYL ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((METHOXYCARBONYL)AMINO)-3-METHYLBUTANOYL)-2-PYRROLIDINYL)-1H-IMIDAZOL-5-YL)-4-BIPHENYLYL)-1H-IMIDAZOL-2-YL)-1-PYRROLIDINYL)CARBONYL)-2-METHYLPROPYL)CARBAMATE DIHYDROCHLORIDE SALT

The present disclosure generally relates to a crystalline form of methyl ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1 H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt. The present disclosure also generally relates to a pharmaceutical composition comprising a crystalline form, as well as methods of using a crystalline form in the treatment of Hepatitis C and methods for obtaining such crystalline form.